Premium
Ikena Oncology Inc (IKNA)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.11 | -7.58620689655 | 1.45 | 1.465 | 1.33 | 78050 | 1.39206928 | CS |
| 4 | -0.16 | -10.6666666667 | 1.5 | 1.6 | 1.33 | 164825 | 1.4421865 | CS |
| 12 | -0.366 | -21.4536928488 | 1.706 | 1.94 | 1.33 | 254030 | 1.58288696 | CS |
| 26 | -0.4 | -22.9885057471 | 1.74 | 1.94 | 1.33 | 140437 | 1.60914954 | CS |
| 52 | -0.17 | -11.2582781457 | 1.51 | 1.94 | 1.22 | 208269 | 1.56556349 | CS |
| 156 | -5.19 | -79.4793261868 | 6.53 | 8.99 | 1.02 | 175867 | 2.82685588 | CS |
| 260 | -21.06 | -94.0178571429 | 22.4 | 37.61 | 1.02 | 170535 | 5.56182976 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
